Intratumoral Oncolytic Virus V937 Plus Pembrolizumab in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Immunology, Immunotherapy: CII
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Cancer Immunol. Immunother. 2022 Nov 29;[EPub Ahead of Print], AW Silk, SJ O'Day, HL Kaufman, J Bryan, JT Norrell, C Imbergamo, D Portal, E Zambrano-Acosta, M Palmeri, S Fein, C Wu, L Guerreiro, D Medina, PK Bommareddy, A Zloza, BA Fox, C Ballesteros-Merino, Y Ren, D Shafren, M Grose, JA Vieth, JM MehnertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.